Clinical Trials

A Pilot Study of Xifaxan to Treat Patients With PSC

Location:

Rochester, MN

Trial status:

Open for Enrollment

Why is this study being done?

In the current protocol, we propose the assessment of potential beneficial effects of the antibiotic Xifaxan on liver biochemistries, liver related symptoms and Mayo risk score in 15 adult and 5 pediatric patients with PSC. Adult patients will receive Xifaxan, 550 mg twice daily over a 12-week period. Pediatric patients with PSC whose weight is greater than or equal to 40 kg will receive Xifaxan, 550 mg twice daily.

Last updated: 03/26/2013

NCT ID:

NCT01695174